Clarity Needed Amidst Tomato Contamination...(and other familyfavorites. For more i...),Health
Navigation Links
Clarity Needed Amidst Tomato Contamination Confusion
Date:6/11/2008
and other family favorites.
For more information, tips and recipes, go to TomatoWellness.com.
About the Tomato Products Wellness Council (TPWC)
TPWC funds scientific research on tomato products and their link to helping reduce the risk of cardiovascular disease, cancer, diabetes and obesity. Its members are tomato growers, processors and product manufacturers.
'/>"/>
| SOURCE Tomato Products Wellness Council Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
2. Clarity on Cosmetic Injectable Labeling and Use
3. Clarity for Consumers on Botox Complication and Death Reports
4. Experts Offer Clarity on Confusion Surrounding Stents
5. A New Kind of New Years Resolution Could Bring Clarity to Americans
6. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
7. Incidental adrenal masses commonly seen on CT are usually benign; no follow-up needed
8. ACP says major system reforms needed to improve the state of primary care medicine in the US
9. Suicide Prevention Group Delivers Much-Needed Message to Pennsylvanias Elderly
10. Aid Urgently Needed in Myanmar (Burma): Lutheran World Relief Responds
11. New Report Reveals Students Lack Awareness of Resources Needed by Pregnant and Parenting College Students: Perception is Reality
Post Your Comments:
(Date:12/4/2008)...TLAKE, Texas, Dec. 4 Mid... today announced that it has opened its,administr...mpany,s Germantown,facility will continue to hous...leBrook,s research and development group. The new... expected to house up to 60 employees as MiddleBro...
(Date:12/4/2008)... ARBOR, Mich., Dec. 4 BAPTIST HEAL...rk., and the state,s largest health system, has,e...om Thomson Reuters -- a,solution that enabled the...al,interventions and save more than $1 million. ,...ittle Rock campus show that,CareFocus prompts app...
(Date:12/4/2008)...e effects similar to those seen with standard dose...AY, Dec. 4 (HealthDay News) -- A high dose of the ...for patients with previously untreated acute myelo...sponsored by the U.S. National Cancer Institute (N...ne marrow. This study included 633 patients, aged ...
(Date:12/4/2008)...ctronic AIDS Quilt Unites Leaders of Virginia, Mar... Dec. 4 Nationally, Was...e living with AIDS in D.C., 82 percent are African...this crisis in D.C. and the South, today,s Living ...ity brought together the leaders of the Virginia,...
Breaking Medicine News(10 mins):Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 3Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 4Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 2Health News:Southern AIDS Living Quilt Raises Awareness in Washington, D.C. 3[0] Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas[0] BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy[0] Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients[0] Southern AIDS Living Quilt Raises Awareness in Washington, D.C.
...titute of Medical Research (MIMR) have developed a...ich allowed scientists// to monitor preterm babies...nd in Australia, helped doctors to monitor continu...rain oxygen levels of a preterm babies. Scientis...
...inian doctor and five Bulgarian nurses who have be...as resumed //in the Libyan capital, Tripoli. Thre...children as prosecution witnesses in a Libyan cour...women as the nurses who knowingly infected 400 chi...
...cted by Stephanie Chiuve it was found that a healt... ailments//. U.S. researchers stated that patient...n benefit if they alter their lifestyle. It was d...an reduce their heart problems by 57% if they main...
...besity-related risk factors have indicated that mo...ence of health risks// like hypertension, diabetes...of obesity played a main role in predisposing wome...rchers reported from an observational study. Obes...
Other Medicine News:Health News:Preterm Babies Benefited from a New NI Spectroscopy 2Health News:Obese Women are more likely to suffer from Major Health Risks 2Health News:Obese Women are more likely to suffer from Major Health Risks 3(Date:12/2/2008)...wire-FirstCall/ -- Biopure Corporation,(Nasdaq: ...l Research Center,(NMRC) has submitted to the Foo...gational new drug (IND) application to conduct a c... Hemopure(R) [hemoglobin glutamer - 250 (bovine)],...uma patients. The study is,entitled "Operation Re...
(Date:12/2/2008).../ -- Horizon Therapeutics, Inc., a,privately held...wo pivotal,Phase 3 trials evaluating its lead inv...primary endpoints. HZT-501, a novel, proprietary f...n and famotidine, demonstrated a,statistically si...dal,anti-inflammatory drug (NSAID)-induced upper ...
(Date:12/1/2008)...2 A study has found tha...ique for imaging the breast, is not affected by ei...two factors that limit the effectiveness of standa...s will be presented today at the annual meeting of... , , "The ability of PEM to detect cancer ...
(Date:12/1/2008)...- S*BIO Pte Ltd today announced the initiation of ... orally-active JAK2 inhibitor, in leading medical ...opathic myelofibrosis (CIMF). , , The tria...ity of SB1518 in patients with CIMF and is expecte... the study will assess the safety profile and eval...
Breaking Medicine Technology:U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Minorities More Likely to Die in ER 27526 1Minorities More Likely to Die in ER 27526 2Minorities More Likely to Die in ER 27526 3Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 1Coleman Natural 28R 29 Foods Launches New and Improved Website 27523 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 1Douglas Oberhelman Elected to Lilly Board of Directors 8390 2Douglas Oberhelman Elected to Lilly Board of Directors 8390 3Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 1Sandia SES win Popular Mechanics Breakthrough Innovator Award 5467 2[0] U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting[0] Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints[2] New Mammography Technology Effective in Detecting Breast Cancer[0] S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
...DGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - Combin... preliminary results of,a phase 2 clinical trial s...prednisolone and the antidepressant paroxetine),an...oid arthritis,(RA). This trial served two importan...t of 3mg of prednisolone alone (a very low dose),i...
...Y, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek,P...sentation of,positive Phase 2 clinical data demons...ntial for INO-1001 as a preventative agent for,car...n subjects,with acute ST-elevated myocardial infar...nary intervention. The presentation was,made in a ...
Other Medicine Technology:CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 3CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 5CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 6Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose PrednisoloneInotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
...X/See™ is a 1-step, hand-held, point-of-care...rug metabolites in human urine. The TOX/See devic...d drugs in 3 to 8 minutes and requires only a few ...lly packaged to maximize convenience and ease of u...
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |